BRPI0509465A - método para o diagnóstico de uma predisposição para desenvolver doença trombótica e seus usos - Google Patents

método para o diagnóstico de uma predisposição para desenvolver doença trombótica e seus usos

Info

Publication number
BRPI0509465A
BRPI0509465A BRPI0509465-8A BRPI0509465A BRPI0509465A BR PI0509465 A BRPI0509465 A BR PI0509465A BR PI0509465 A BRPI0509465 A BR PI0509465A BR PI0509465 A BRPI0509465 A BR PI0509465A
Authority
BR
Brazil
Prior art keywords
predisposition
diagnosing
thrombotic disease
develop
develop thrombotic
Prior art date
Application number
BRPI0509465-8A
Other languages
English (en)
Inventor
Detlef Kozian
Matthias Hermann
Jean-Francois Deleuze
Sylvain Ricard
Sandrine Mace
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of BRPI0509465A publication Critical patent/BRPI0509465A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"MéTODO PARA O DIAGNóSTICO DE UMA PREDISPOSIçãO PARA DESENVOLVER DOENçA TROMBóTICA E SEUS USOS". A presente invenção refere-se a um método para o diagnóstico de uma predisposição para desenvolver doença trombótica, a sistemas de teste e seu uso para o diagnástico de uma predisposição para desenvolver doença trombótica, a uma variação do promotor de P2X1 e seu uso para selecionar um agente antitrombótico e a métodos para identificar um indivíduo que possa ser tratado de forma profilática ou terapêutica com um agente antitrombótico ou para adaptar uma dose terapêutica ou profilática de um agente antitrombótico.
BRPI0509465-8A 2004-03-29 2005-03-16 método para o diagnóstico de uma predisposição para desenvolver doença trombótica e seus usos BRPI0509465A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04007511A EP1582597A1 (en) 2004-03-29 2004-03-29 Method of diagnosis of a predisposition to develop thrombotic disease and its uses
US60575704P 2004-08-31 2004-08-31
PCT/EP2005/002761 WO2005095642A1 (en) 2004-03-29 2005-03-16 Method of diagnosis of a predisposition to develop thrombotic disease and its uses

Publications (1)

Publication Number Publication Date
BRPI0509465A true BRPI0509465A (pt) 2007-09-11

Family

ID=34878183

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509465-8A BRPI0509465A (pt) 2004-03-29 2005-03-16 método para o diagnóstico de uma predisposição para desenvolver doença trombótica e seus usos

Country Status (11)

Country Link
US (2) US7785781B2 (pt)
EP (2) EP1582597A1 (pt)
JP (1) JP2007530059A (pt)
KR (1) KR20070004804A (pt)
CN (1) CN1938431A (pt)
AU (1) AU2005229374B2 (pt)
BR (1) BRPI0509465A (pt)
CA (1) CA2560838A1 (pt)
IL (1) IL178057A0 (pt)
SG (1) SG136150A1 (pt)
WO (1) WO2005095642A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3081979C (en) 2011-12-01 2023-07-11 F. Hoffmann-La Roche Ag Nt-proanp and nt-probnp for the diagnosis of stroke
US20140128270A1 (en) * 2012-11-08 2014-05-08 Roche Molecular Systems, Inc. Method of improving microarray performance by strand elimination

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides

Also Published As

Publication number Publication date
AU2005229374A1 (en) 2005-10-13
EP1582597A1 (en) 2005-10-05
US20080038722A1 (en) 2008-02-14
US7785781B2 (en) 2010-08-31
KR20070004804A (ko) 2007-01-09
IL178057A0 (en) 2006-12-31
CA2560838A1 (en) 2005-10-13
EP1733049A1 (en) 2006-12-20
JP2007530059A (ja) 2007-11-01
AU2005229374B2 (en) 2010-12-23
WO2005095642A1 (en) 2005-10-13
CN1938431A (zh) 2007-03-28
SG136150A1 (en) 2007-10-29
US20100221738A1 (en) 2010-09-02

Similar Documents

Publication Publication Date Title
Hodes et al. Disease drivers of aging
Maj et al. Reliability and validity of the DSM-IV diagnostic category of schizoaffective disorder: preliminary data
Mehlsen et al. No indications of cognitive side‐effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy
Wenk Neuropathologic changes in Alzheimer's disease: potential targets for treatment
BRPI0510274B8 (pt) uso de um agente para tratar ou prevenir doença celíaca, composição farmacêutica compreendendo dito agente, método de diagnóstico de doença celíaca, ou suscetibilidade à doença celíaca, uso do dito agente para a preparação de um meio de diagnóstico e kit para realizar o dito método de diagnóstico
BRPI0406689A (pt) Uso de um anticorpo bd16 e/ou bb18 anti-cd100 e método in vitro para diagnóstico ou determinação da evolução de um distúrbio inflamatório
Nunes et al. Independent versus substance-induced major depressive disorder in substance-dependent patients: observational study of course during follow-up
BR112013013460A8 (pt) métodos de identificação de um paciente com asma, método de monitoramento de um paciente com asma, uso de um kit de detecção de periostina total, kit de medição da periostina total, uso de um anticorpo anti-il-13, uso de uma quantidade terapeuticamente eficaz de lebrikizumab, uso de um inibidor da via de th2, método de avaliação de eventos adversos, anticorpo anti-periostina e teste de periostina total
Morichi et al. Diagnosing and treating depression in older and oldest old
Caplette-Gingras et al. Depression in women with metastatic breast cancer: a review of the literature
BRPI0921999B8 (pt) uso de uma quantidade terapeuticamente eficaz de células tronco placentárias
WO2007103373A3 (en) Compositions and methods for the treatment of immunoinflammatory disorders
BR0308290A (pt) Tratamento e prevenção de distúrbios inflamatórios
GT200900049A (es) Derivados de 2-aril-6-fenil-imidazo [1,2-a]piridinas, su preparacion y su aplicacion terapeutica
Burckhardt et al. Pain-coping strategies of women with fibromyalgia: relationship to pain, fatigue, and quality of life
BRPI0911482A2 (pt) Uso de epotilona d no tratamento de doenças associadas a tau incluindo doenças de alzheimer
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
Foster et al. Positive and negative effects of internalizing on alcohol use problems from childhood to young adulthood: The mediating and suppressing role of externalizing.
EP0824917A3 (en) Use of a serotonin 5-HTlf agonist in the manufacture of a medicament for treating or ameliorating the symptoms of common cold or allergic rhinitis
Kumar et al. Effect of chlorhexidine chip in the treatment of chronic periodontitis
ES2194116T3 (es) Procedimiento para detectar anticuerpos antipolimero y kit de prueba de diagnostico para uso como ayuda al diagnostico de las enfermedades relacionadas con silicona.
BRPI0509465A (pt) método para o diagnóstico de uma predisposição para desenvolver doença trombótica e seus usos
WO2005065668A3 (en) Topical compositions comprising halo-deoxyadenosines for treatment of skin disorders
UY39061A (es) Inhibidores macrocíclicos de rip2-cinasa
Serrano-Dueñas et al. Properties of the Apathy Scale (AS) for use on Parkinson’s patients

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B10A Cessation: cessation confirmed

Free format text: HOMOLOGADA A DESISTENCIA DO PEDIDO, SOLICITADA ATRAVES DA PETICAO NO 020120004050/RJ DE 16/01/2012.